Recursion Pharmaceuticals, INC Form 4 insider transactions

Director Terry-Ann Burrell reports acquisition of restricted stock units and stock options in Recursion Pharmaceuticals.

Director Robert Hershberg receives stock options and restricted stock units from Recursion Pharmaceuticals.

Director Blake Borgeson receives stock options and restricted stock units from Recursion Pharmaceuticals.

Director Dar Zavain received restricted stock units and stock options from Recursion Pharmaceuticals on June 3, 2024.

Director Dean Y. Li reports the acquisition of restricted stock units and stock options in Recursion Pharmaceuticals, granted on June 3, 2024, according to the company's Outside Director Compensation Policy.

Tina Marriott, President and COO of Recursion Pharmaceuticals, executed stock transactions involving the sale of 3,000 shares of Class A Common Stock at an average price of $8.775, and the exercise of stock options to acquire 3,000 shares at $1.06, according to a recent SEC Form 4 filing.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on May 28, 2024, under a pre-arranged 10b5-1 trading plan.

Tina Marriott, President and COO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations.

David J. Mauro, Chief Medical Officer of Recursion Pharmaceuticals, reports the disposal of 867 shares to cover tax obligations related to restricted stock units.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the withholding of shares to cover tax obligations and ongoing vesting of stock options.

Michael Secora, CFO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Director Blake Borgeson of Recursion Pharmaceuticals sold 20,054 shares of Class A Common Stock at an average price of $10.1194 under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of Class A Common Stock and the conversion of Class B Common Stock into Class A Common Stock, according to a recent SEC Form 4 filing.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.9465 on April 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson sold shares of Recursion Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Christopher Gibson reported the sale of Class A Common Stock and conversion of Class B Common Stock into Class A Common Stock, according to a recent SEC Form 4 filing.

Director Dean Y. Li reports acquiring shares of Recursion Pharmaceuticals through the company's Outside Director Compensation Policy.

R. Martin Chavez, a director at Recursion Pharmaceuticals, acquired 2,001 shares of Class A Common Stock on April 1, 2024, under the company's Outside Director Compensation Policy.

Zavain Dar, a director at Recursion Pharmaceuticals, reported acquiring 1,467 shares of Class A Common Stock on April 1, 2024, and disclosed previously unreported shares received from a pro-rata distribution.

Director Terry-Ann Burrell acquired 1,467 shares of Recursion Pharmaceuticals' Class A Common Stock on April 1, 2024, under the company's Outside Director Compensation Policy.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on April 2, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of 65,000 shares of Class A Common Stock and the conversion of 25,000 shares of Class B Common Stock into Class A Common Stock on March 28, 2024.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson of Recursion Pharmaceuticals sold 20,054 shares of Class A Common Stock on March 19, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions, as part of a pre-arranged trading plan.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock at an average price of $12.0577 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.